BURKIMAB14: dose reduction of chemotherapy in young adults with Burkitt lymphoma

Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, comments on the results of the Phase II BURKIMAB14 trial (NCT05049473) evaluating the feasibility of dose reduction of chemotherapy after complete metabolic response (CMR) in young adults with Burkitt lymphoma and leukemia. The results demonstrated that this regimen decreased toxicity and did not have an impact on outcomes. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.